To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

OTA 2020: Predictors of Serious Adverse Events in Hip Fracture - Subanalysis of the HEALTH Trial

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
October 2020

OTA 2020: Predictors of Serious Adverse Events in Hip Fracture - Subanalysis of the HEALTH Trial

Vol: 9| Issue: 10| Number:33| ISSN#: 2564-2537
Study Type:N/A
OE Level Evidence:N/A
Journal Level of Evidence:N/A

Predictors of Medical Serious Adverse Events in Hip Fracture Patients: A Subanalysis of the HEALTH Trial

Contributing Authors:
D Neilly D Macdonald S Sprague S Bzovsky D Axelrod RW Poolman F Frihagen D Heels-Ansdell M Bhandari E Schemitsch I Stevenson The HEALTH Investigators

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

A total of 1441 patients in the HEALTH trial who received total hip arthroplasty or hemiarthroplasty for a femoral neck fracture were included in this sub-analysis assessing the incidence of serious adverse events and factors associated with serious adverse events. Of the 1441 patients analyzed, 370 patients experienced a serious adverse event. The most common serious adverse events were cardiac (...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue